Ocena in vitro grzybow z rodzaju Aspergillus i Penicillium na nowe leki przeciwgrzybicze

• Autorzy: Macura A B , Pawlik B. , Szczepko I.
• Języki publikacji: PL

Abstrakty

EN

Fifty four mould strains (32 Aspergillus and 22 Penicillium) isolated from clinical materials were tested using dilution method. Two test media were used: Yeast Nitrogen Base (YNB) and Czapek Dox (CD). The following drugs were tested: amorolfine, cyclopirox, itraconazole, and terbinafine. In the dilution method, the drugs were tested at four contrentrations: 0.1 mg/l, 1 mg/l, 10 mg/l, and 100 mg/l. No matter which medium and/or drug was used, terbinafine turned out to be most effective. The drug at a conceatration of 1 mg/l inhibited 88.9% of the strains in the CD medium. The MIC values in the YNB medium varied from 0,1 mg/l through 100 mg/1, however, 50% of the strains were inhibited at 1 mg/l or less. Itraconazole revealed a fairly good in vitro antifungal action, particularly in the CD medium: 77.8% of the strains were inhibited at 10 mg/l or less. Aspergillus fumigatus and Aspergillus flavus were most susceptible to itraconazole. The MIC values of cyclopirox amounted to 100 mg/l for all of the strains in the CD medium but not in the YNB where they varied from 1 mg/l to 100 mg/l. Amorolfine was the least effective drug. Most of the strains were inhibited at a concentration of at least 100 mg/l. The findings give evidence that the susceptibility of Aspergillus and Penicillium to the particular drugs is different, and that the results are influenced by the test medium.

Słowa kluczowe

PL

plesnie; Penicillium; dzialanie lekow; Aspergillus; leki przeciwgrzybicze; parazytologia; ocena; dzialanie przeciwgrzybicze; badania in vitro; grzybice

• Wydawca: -
• Czasopismo: Wiadomości Parazytologiczne
• Rocznik: 2000
• Tom: 46
• Numer: 1
• Opis fizyczny: s.157-162,tab.,bibliogr.

Twórcy

autor

Macura A B

• Uniwersytet Jagiellonski, Czysta 18, 31-121 Krakow

autor

Pawlik B.

autor

Szczepko I.

Bibliografia

• ARMSTKONG D, 1993. Treatment ofopportunistic fungal infections. Clin. Jnfect. Dis. 16: 1-9.
• CLEARLY J. P., TAYLOR J. W., CHAPMAN S. W. 1992. Itraconazole in antifungal therapy. Ann. Pharmacother 26: 502-509.
• GRAYBILL J. R. 1992. Future directions of antifungal chemoterapy. Clin. Jnfect. Dis. 14, suppl. 1: S170-S181.
• LYMAN C., WALSH T. J. 1992. Systemically administered antifungal agents: a review of clinical pharmacology and therapeutic applications. Drug. 44: 9-35.
• MACURA A. B. 1991. Fungal resistance to antimycotic drugs. A growing problem. Inter. J. Dermat. 30: 181-183.
• MACURA A. B. PAWLIK B. 1997. Fungal susceptibility to amorolfine. Mikol. Lek. 4: 85-87.
• MUHLDORFER S. M., KONIG H. J. 1990. Prophylaxis of fungal infections with itraconazole in immunocompromised cancer patients. Mycoses. 33: 291-295.
• PAWLIK B., MACURA A. B. 1997. The susceptibility of fungi from lesion isolates to terbinafine. Mikol. Lek. 4: 11-14.
• RINGEL S. M. 1996. New antifungal agents for the systemie mycoses. Mycopathologia 109: 75-87.
• VARTHALITIS L, MEUNIER F. 1995. Invasive fungal infections in cancer patients. Prophylaxis of fungal infections. Bailliere's Clinical Infections Diseases 2: 157-177.